(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of 55.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Macrogenics's revenue in 2024 is $58,749,000.On average, 3 Wall Street analysts forecast MGNX's revenue for 2024 to be $3,808,540,089, with the lowest MGNX revenue forecast at $2,936,801,892, and the highest MGNX revenue forecast at $4,769,805,793. On average, 2 Wall Street analysts forecast MGNX's revenue for 2025 to be $13,688,843,170, with the lowest MGNX revenue forecast at $7,011,115,060, and the highest MGNX revenue forecast at $20,366,571,281.
In 2026, MGNX is forecast to generate $9,532,744,065 in revenue, with the lowest revenue forecast at $9,532,744,065 and the highest revenue forecast at $9,532,744,065.